Aravive, Inc (ARAV)

Etorro trading 970x250
Aravive, Inc (ARAV) Logo

About Aravive, Inc

Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases. Its lead product candidate is AVB-500, a decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase Ib/II clinical trial for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the treatment of clear cell renal cell carcinoma, HER negative breast cancer, uterine, pancreatic cancer, urothelial, and non-small-cell lung cancers. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a strategic collaboration agreement with WuXi Biologics to develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain AVB-500 as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. is headquartered in Houston, Texas. Address: River Oaks Tower, Houston, TX, United States, 77098

Aravive, Inc News and around…

Latest news about Aravive, Inc (ARAV) common stock and company :

The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
07 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal
06 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout
05 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Aravive to Present New Preliminary Data from Phase 1b Trial Evaluating AVB-500 in Clear Cell Renal Cell Carcinoma at 2021 Society for Immunotherapy of Cancer Annual Meeting
01 Oct, 2021 Yahoo! Finance

HOUSTON, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced that new preliminary safety, pharmacokinetic, pharmacodynamic, and clinical activity data from the Phase 1b portion of its open-label Phase 1b/2 trial evaluating AVB-500 in combination with cabozantinib in patients with clear cell renal cell carcinoma (ccRCC) will be presented at the Society for Immunothe

Implied VXF Analyst Target Price: $218
28 Sep, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Extended Market ETF (VXF), we found that the implied analyst target price for the ETF based upon its underlying holdings is $217.84 per unit.

Aravive to Participate in Fireside Chat at Cantor Fitzgerald Virtual Global Healthcare Conference
16 Sep, 2021 FinancialContent
Aravive to Participate in Fireside Chat at H.C. Wainwright 23rd Annual Global Investment Conference
01 Sep, 2021 FinancialContent
Look Under The Hood: VXF Has 15% Upside
24 Aug, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Extended Market ETF (VXF), we found that the implied analyst target price for the ETF based upon its underlying holdings is $213.01 per unit.

The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data
20 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
18 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
17 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Aravive Announces First Patient Dosed in Phase 1b/2 Clinical Trial of AVB-500 for the Treatment of Pancreatic Adenocarcinoma
09 Aug, 2021 FinancialContent
Aravive Reports Second Quarter 2021 Financial Results and Provides Corporate Updates
05 Aug, 2021 FinancialContent
The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal
28 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Aravive to Participate in Fireside Chat at 2021 BTIG Biotechnology Conference
27 Jul, 2021 FinancialContent
Aravive Achieves Second Development Milestone from 3D Medicines
15 Jul, 2021 FinancialContent

Milestone is Based on Approval of 3D Medicines’ IND in China to Participate in Aravive’s AVB-500 (3D-299) Phase 3 Clinical Trial for Platinum Resistant Ovarian Cancer

Aravive to Participate in Fireside Chat at 2021 William Blair Biotech Focus Conference
07 Jul, 2021 FinancialContent
12 Health Care Stocks Moving In Thursday's After-Market Session
01 Jul, 2021 FinancialContent

Gainers Alterity Therapeutics (NASDAQ:ATHE) stock moved upwards by 13.55% to $2.43 during Thursday's after-market session. Today's ...

Hedge Fund Sentiment Is Stagnant On Aravive, Inc. (ARAV)
29 Jun, 2021 Yahoo! Finance

In this article we will take a look at whether hedge funds think Aravive, Inc. (NASDAQ:ARAV) is a good investment right now. We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, unconventional data sources, expert networks, and get tips from […]

12 Health Care Stocks Moving In Friday's Pre-Market Session
25 Jun, 2021 FinancialContent

Gainers Osmotica Pharmaceuticals (NASDAQ:OSMT) shares increased by 39.08% to $3.95 during Friday's pre-market ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
25 Jun, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips We're back at it again with another look at the biggest pre-market stock movers for Friday as the perfect way to close out the week. The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now It doesn’t matter if you have $500 in savings or $5 million. Do this now. Top Stock Picker Reveals His Next Potential 500% Winner

45 Biggest Movers From Yesterday
25 Jun, 2021 FinancialContent

Gainers Marin Software Incorporated (NASDAQ: MRIN) shares surged 105.3% to close at $3.51 on Thursday after the company announced ...

36 Stocks Moving In Thursday's Mid-Day Session
24 Jun, 2021 FinancialContent

Gainers Marin Software Incorporated (NASDAQ: MRIN) jumped 58% to $2.70 after the company announced it has added the ability to ...

Mid-Morning Market Update: Markets Open Higher; Accenture Reports Upbeat Q3 Results
24 Jun, 2021 FinancialContent

Following the market opening Thursday, the Dow traded up 0.76% to 34,130.38 while the NASDAQ rose 0.75% to 14,379.10. The S&P also ...

12 Health Care Stocks Moving In Thursday's Pre-Market Session
24 Jun, 2021 FinancialContent

Gainers Aravive (NASDAQ:ARAV) stock moved upwards by 21.61% to $6.47 during Thursday's pre-market session. The ...

Aravive Announces Positive Initial Results from Phase 1b Portion of the Phase1b/2 Study of AVB-500 in Combination with Cabozantinib in Clear Cell Renal Carcinoma
24 Jun, 2021 FinancialContent

Encouraging Pharmacokinetics, Pharmacodynamics and Safety Profile at 15mg/kg of AVB-500

Aravive Higher on Progress in Phase 1b Trial of Kidney-Cancer Drug
24 Jun, 2021 Yahoo! Finance

Aravive shares jumped after the oncology-drug specialist reported progress in a trial of a drug to treat kidney cancer.

Aravive Announces Three New Appointments to its Board of Directors
18 May, 2021 FinancialContent

Further Strengthens Senior Executive Leadership Team

Look Under The Hood: VXF Has 18% Upside
13 May, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Extended Market ETF (VXF), we found that the implied analyst target price for the ETF based upon its underlying holdings is $202.67 per unit.

Aravive (ARAV) Reports Q1 Loss, Lags Revenue Estimates
06 May, 2021 Yahoo! Finance

Aravive (ARAV) delivered earnings and revenue surprises of 2.22% and -54.69%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Aravive, Inc (ARAV) is a NASDAQ Common Stock listed in , ,

970x250